In accordance with its responsibility for its products and the health of the consumers, JSC «Grindeks» continues to develop its pharmacovigilance system in all sales markets. For the purpose of elimination of potential risks and health hazards, data on the effects of the medicinal products are being summarised, investigated and evaluated and information about the side-effects and interactions of medicinal products is being gathered.
The analysis of the reports and their further submission to the competent authorities are carried out in accordance with the relevant guidelines and pharmaceutical company practices. «Grindeks» is involved in the electronic reporting system EudraVigilance which is also the main European Risk Management Strategy support between the EMEA (European Medicines Agency) and the competent national authorities.
To ensure control of safe drug administration, there is the Pharmacovigilance group at the company, which key task is to state and timely eliminate adverse/side effects from drug administration and report to the competent authorities.
Please, inform if you have side or adverse effects while administrating «Grindeks» drugs.
Manager of Pharmacovigilance Group
e-mail: email@example.com, firstname.lastname@example.org